Biohaven Ltd
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
BHVN$15.11-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(Amounts in thousands)
| Year ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Cash flows from operating activities: | |||
| Net loss | $(408,168) | $(570,279) | $(213,796) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Non-cash share-based compensation | 28,787 | 193,556 | 65,639 |
| Acquisition of IPR&D asset | — | 93,747 | — |
| Impairment of Artizan preferred stock | — | 10,000 | — |
| Depreciation and amortization | 6,912 | 1,386 | 1,393 |
| Issuance of Former Parent common shares as payment for license and consulting agreements | — | 1,779 | 7,929 |
| Issuance of common shares as payment for license agreement | 21,814 | — | — |
| Gain from equity method investment | — | — | (5,261) |
| Other non-cash items | (5,683) | 726 | (3,408) |
| Changes in operating assets and liabilities: | |||
| Prepaid expenses, income tax receivable, and other current and non-current assets | 27,176 | (41,336) | (9,182) |
| Accounts payable | 4,874 | 5,928 | 1,025 |
| Accrued expenses and other current and non-current liabilities | (7,437) | 6,804 | 9,821 |
| Net cash used in operating activities | $(331,725) | $(297,689) | $(145,840) |
| Cash flows from investing activities: | |||
| Proceeds from maturities of marketable securities | 322,079 | — | — |
| Proceeds from sales of marketable securities | 4,920 | — | — |
| Purchases of marketable securities | (194,121) | (259,716) | — |
| Purchases of property and equipment | (3,048) | (6,074) | (938) |
| Payment for IPR&D asset acquisition | — | (35,000) | — |
| Cash acquired in business acquisition | — | — | 1,882 |
| Purchase of Artizan preferred stock | — | (4,000) | — |
| Net cash provided by (used in) investing activities | $129,830 | $(304,790) | $944 |
| Cash flows from financing activities: | |||
| Net transfers from Former Parent | — | 449,130 | 138,052 |
| Change in restricted cash due to Former Parent | (35,212) | 35,212 | — |
| Proceeds from issuance of common shares | 243,225 | 283,804 | — |
| Payments of issuance costs | (800) | (1,000) | — |
| Proceeds from issuance of common shares under 2022 Equity Incentive Plan and employee share purchase plan | 4,695 | 451 | 395 |
| Net cash provided by financing activities | $211,908 | $767,597 | $138,447 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | (497) | 429 | — |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 9,516 | 165,547 | (6,449) |
| Cash, cash equivalents and restricted cash at beginning of period | 242,604 | 77,057 | 83,506 |
| Cash, cash equivalents and restricted cash at end of period | $252,120 | $242,604 | $77,057 |
| Supplemental disclosure of cash flow information: | |||
| Cash paid for interest | $— | $— | $107 |
| Cash (received) paid for income taxes | $(33,300) | $38,165 | $16,594 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.